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All of us cardiologists have been asked about vaccination against yellow fever during consultations, as well as in phone calls or messages from patients or family members. The reason is that the outbreak of the disease has appeared on the news daily causing the whole country to worry.
Even in the absence of a consensus on universal vaccination, the current epidemiological situation requires the intensification of measures in the short term due to the risk of triggering a catastrophic urban epidemic with high morbidity and mortality.
One of the most difficult decisions involving medical liability is in the recommendation for patients over the age of 60 years, when there is a higher incidence of adverse events that, although rare, can be serious and fatal.
These complications have been reported in studies with the non-fractional vaccine on a regular basis and we do not know if they would be even rarer with the fractional vaccine that is now being used.
It must be understood that this situation is dynamic, like any epidemic or pandemic outbreak, and there is a permanent need for reassessment, clarification and guidance. Thus, public health authorities and medical societies have advised that patients over 60 years should consult their professional for advice, which requires careful evaluation of the epidemiological risk. It is physician's responsibility to define the protection of this age group in the population. If they are not vaccinated and become infected, they can rapidly progress to severe forms that will increase the complications of any underlying conditions. The decision involves comparing the risk of developing complications, estimated for the elderly (with the entire vaccine) at 1 per 100,000 (60 to 70 years-old) or 1 per 30,000 (> 70 years-old) versus 1-2 per 1 million in non-elderly individuals.
Therefore, the Ministry of Health published a generic guide:
Ministry of health -Guide to vaccination criteria aGainst yellow fever Precautions Thorough and individualized risk and benefit assessment for vaccine recommendation is required as follows:
• Acute moderate or severe febrile conditions.
• First yellow fever vaccination in people aged 60 and over.
• Blood or organ donors.
• HIV-infected individuals, asymptomatic and with moderate immunosuppression according to CD4 count.
• People with potentially autoimmune diseases.
• People with hematological diseases.
• Patients who have developed demyelinating neurological disease within 6 weeks after the previous dose of the vaccine.
• Pregnant and breastfeeding women.
Contraindications
• Children under 6 months of age.
• Individuals with a history of severe adverse events with previous doses.
• Those with a history of laboratory-proven anaphylaxis with previous doses or anaphylaxis related to the substances present in the vaccine (chicken egg and its derivatives, bovine gelatine or others).
• Patients with severe immunosuppression of any nature.
• Patients undergoing organ transplantation.
• Patients with previous history of thymus disease.
• Patients with systemic lupus erythematosus.
